Health Condition 1: L209- Atopic dermatitis, unspecified
Conditions
Interventions
Intervention1: Topical Tofacitinib (2%): Applied topically twice daily over eczematous lesion for 6 weeks
Control Intervention1: Topical Crisaborole (2%): Applied topically twice daily over eczematous
Sponsors
School of Tropical Medicine,Kolkata
Eligibility
Inclusion criteria
Inclusion criteria: All cases of mild to moderate Atopic eczema
Exclusion criteria
Exclusion criteria: 1) Patient unwilling to participate 2) Severe Atopic Eczema 3) Active forms of other eczematous or dermatitis, history of disseminated or recurrent herpes zoster infection 4) Severely ill patients requiring hospitalization less than 6 months prior to the study 5) Any active infection 6) On treatment -oral or topical less than 2 weeks prior to the study 7) History of lymphoproliferative disorders or malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare safety and efficacy of Tofacitinib and Crisaborole for topical management of mild to moderate Atopic EczemaTimepoint: 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate an effective long term steroid free topical maintenance therapy for management of mild to moderate eczemaTimepoint: 6 weeks | — |
Countries
India
Contacts
Public ContactDr Rubina Sultana
School of Tropical Medicine
Outcome results
None listed